Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Front Immunol. 2022 Sep 15;13:1014861. doi: 10.3389/fimmu.2022.1014861. eCollection 2022.
Immune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the response to atezolizumab in urothelial carcinoma patients.
A total of 298 advanced urothelial carcinoma patients with response data in the IMvigor210 cohort were included. Differential expressions of 23 m6A methylation regulators in different treatment outcomes were conducted. Subsequently, a gene signature was developed in the training set using the least absolute shrinkage and selection operator (LASSO) regression. Based on the multivariable logistic regression, a nomogram was constructed by incorporating the gene signature and independent clinicopathological predictors. The performance of the nomogram was assessed by its discrimination, calibration, and clinical utility with internal validation.
Six m6A methylation regulators, including , , , , , and , were significantly differentially expressed between the responders and non-responders. These six regulators were also significantly correlated with the treatment outcomes. Based on the LASSO regression analysis, the gene signature consisting of two selected m6A methylation regulators ( and ) was constructed and showed favorable discrimination. The nomogram integrating the gene signature, TMB, and PD-L1 expression on immune cells, showed favorable calibration and discrimination in the training set (AUC 0.768), which was confirmed in the validation set (AUC 0.755). Decision curve analysis confirmed the potential clinical usefulness of the nomogram.
This study confirmed the prognostic value of and , and constructed a nomogram for individualized prediction of the response to atezolizumab in patients with urothelial carcinoma, which may aid in making treatment strategies.
免疫检查点阻断剂在尿路上皮癌中显示出生存优势,而有些患者获益最小或出现副作用。因此,我们旨在研究 m6A 甲基化调节剂的预后价值,并开发一个预测尿路上皮癌患者对阿替利珠单抗反应的列线图。
共纳入 298 例 IMvigor210 队列中具有反应数据的晚期尿路上皮癌患者。对不同治疗结果的 23 个 m6A 甲基化调节剂的差异表达进行了分析。随后,使用最小绝对收缩和选择算子(LASSO)回归在训练集中开发了一个基因特征。基于多变量逻辑回归,通过纳入基因特征和独立的临床病理预测因子,构建了一个列线图。通过内部验证评估了列线图的性能,包括其区分度、校准度和临床实用性。
在应答者和无应答者之间,有 6 个 m6A 甲基化调节剂,包括、、、、、和,差异表达显著。这六个调节剂也与治疗结果显著相关。基于 LASSO 回归分析,构建了一个由两个选定的 m6A 甲基化调节剂(和)组成的基因特征,表现出良好的区分度。整合基因特征、TMB 和免疫细胞中 PD-L1 表达的列线图,在训练集(AUC 0.768)中表现出良好的校准度和区分度,在验证集(AUC 0.755)中得到了验证。决策曲线分析证实了该列线图的潜在临床应用价值。
本研究证实了和的预后价值,并构建了一个预测尿路上皮癌患者对阿替利珠单抗反应的列线图,这可能有助于制定治疗策略。